Medicine for postoperative recovery treatment of cardiac infarction
Through the Chinese medicine compound prescription nourishes the heart, resolves phlegm and heat, and unblocks blood vessels, the problem of myocardial ischemia and reperfusion injury after myocardial infarction is solved, significantly reduces the area of myocardial infarction, improves heart function, and improves patients' quality of life.
Patent Information
- Application Number
- CN202411257335.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-09
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art cannot effectively solve the problem of myocardial ischemia and reperfusion injury after myocardial infarction, resulting in the impact of patients' prognosis and quality of life.
A compound prescription for Chinese medicine is adopted, including Pinellia ternata, Bamboo Rose, Citrus aurantium, Tangerine peel, Poria cocos, Astragalus, Prince ginseng, Ophiopogon japonicus, Salvia miltiorrhiza, Schisandra chinensis and Cinnamon twig, which nourishes the heart, resolves qi and phlegm heat, and unblocks blood. It can disperse blood stasis, heat, warm yang and promote diuresis, and coordinate the treatment of myocardial infarction and post-disease myocardial ischemia injury.
It significantly reduces the area of myocardial infarction, improves cardiac function, promotes the disappearance of symptoms and the recovery of physical strength and energy in patients. Both clinical and animal experiments have shown good therapeutic effects.
Smart Images

Figure CN118903333A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicine compositions, and particularly relates to a medicine for postoperative recovery treatment of myocardial infarction. Background Art
[0002] With the improvement of people's living standards, the acceleration of urbanization and population aging, the risk factors for cardiovascular diseases in my country have increased year by year, and the incidence of cardiovascular diseases has shown a clear upward trend year by year. The "China Cardiovascular Health and Disease Report" released in 2021 stated that there are 330 million people suffering from cardiovascular diseases, which is the leading cause of death among Chinese residents. Two out of every five deaths are caused by cardiovascular disease. Cardiovascular disease has become an important public health burden in my country, among which acute myocardial infarction is one of the main causes of death from cardiovascular disease.
[0003] Myocardial infarction is caused by the rupture of atherosclerotic plaques, which leads to partial or complete occlusion of the coronary artery, ischemia and hypoxia of the coronary artery, and eventually causes irreversible myocardial necrosis. Its incidence rate increases with age. Serious complications of myocardial infarction include decreased cardiac function, sudden drop in blood pressure, and even cardiogenic shock, which seriously threaten human life. Although related drug thrombolysis, intervention and bypass surgery and other vascular recanalization technologies are constantly developing, they are the most direct and effective treatment measures for AMI and have saved the lives of a large number of patients. However, although early revascularization can effectively reduce the area of myocardial infarction and reduce the mortality rate of patients, many patients suffer from postoperative complications such as heart failure because the necrotic myocardial tissue cannot be fully restored to a normal state. In addition, although the above-mentioned intervention treatment can re-perfuse blood after myocardial ischemia, the reperfusion process will cause apoptosis and inflammatory damage of myocardial cells in the blood supply area, which is called myocardial ischemia-reperfusion injury, which seriously affects the prognosis and quality of life of patients. Therefore, safe and effective treatment strategies and multi-faceted synergistic therapeutic drugs are urgently needed to improve its treatment efficiency. Summary of the invention
[0004] The present invention aims to provide a drug with good therapeutic effect on improving myocardial infarction and myocardial ischemic damage after the disease, so as to solve the limitations of vascular recanalization technologies such as thrombolysis, intervention and bypass surgery using Western medicine in the existing technology and the clinical problem of ischemic reperfusion myocardial damage that needs to be solved urgently.
[0005] A drug for postoperative recovery treatment of myocardial infarction in this scheme includes the following raw materials within the weight range: 5-10g of Pinellia ternata, 5-10g of Rhizoma Anemarrhenae, 5-10g of Immature Citrus Aurantium, 10-15g of Citrus Reticulatae, 5-15g of Poria, 10-20g of Astragalus, 10-20g of Pseudostellariae Radix, 10-15g of Ophiopogon japonicus, 10-15g of Salvia miltiorrhiza, 10-15g of Schisandrae Chinensis, and 5-10g of Cinnamon Twig.
[0006] Furthermore, the dosage of each raw material is: 10g of Pinellia ternata, 10g of Rhizoma Anemarrhenae, 10g of Immature Citrus aurantium, 15g of Citrus reticulatae, 7.5g of Poria, 15g of Astragalus, 10g of Pseudostellariae Radix, 10g of Ophiopogon japonicus, 10g of Salvia miltiorrhiza, 10g of Schisandrae Chinensis, and 5g of Cinnamon Twig.
[0007] Myocardial infarction belongs to the category of "true heart pain" in traditional Chinese medicine. Combined with the fact that patients in today's era eat fatty and sweet foods and lack exercise, they often suffer from the coexistence of phlegm-heat syndrome in the Qi division and heat-yin damage in the Ying division. Qi and Ying division should be treated together, but in the process of medication, according to the "Yang-tonifying Principle" of Ye Tianshi, a master of warm diseases, the yin and Ying division of the heart are nourished by the yin and yin of the heart, which hinders qi transformation and affects the elimination of phlegm-heat in the Qi division. If the phlegm-heat in the Qi division is not eliminated, it will also cause the Ying division heat to be depressed and difficult to penetrate. This creates a dilemma for the disease caused by complex pathogenesis, manifested as yang deficiency, qi weakness, dampness and heat, and phlegm-heat blocking the heart, leading to blood stasis and heat accumulation in the heart meridians, and deep blood heat dissipating in the Wei surface Yang meridians.
[0008] Another example is acute and chronic myocardial infarction and its late stages accompanied by symptoms such as heart failure and lower limb edema. Traditional Chinese medicine believes that most patients suffer from yang deficiency and are more afraid that nourishing yin drugs will hinder qi transformation. Therefore, the taste and dosage of nourishing yin drugs are further reduced, and replaced with warming yang and diuretic products to assist in resolving phlegm and heat in the qi. The clinical application effect is significant.
[0009] On this basis, based on Ye Tianshi's "Qi Meridian-Blood Collaterals" theory, "dampness and heat in the meridians at the beginning of the disease, and blood damage entering the collaterals after a long time", the pathological evolution path, "divided elimination and drainage" and "Qi Ying co-treatment" basic treatment methods, according to many years of clinical experience, the drug described in the present invention has been expanded and innovated, which has a good effect on improving myocardial infarction and myocardial ischemia damage after the disease. Among them, Pseudostellariae Radix, Astragalus and Schisandrae Chinensis can replenish qi, generate yang and eliminate dampness, while Pinellia, Rhizoma Anemarrhenae, Citrus Aurantii, Citrus Reticulatae, Poria and the like can eliminate dampness and heat in the triple burner and phlegm dampness. Ophiopogon japonicus and Salvia miltiorrhiza can resolve blood stasis, disperse blood heat, and dredge blood collaterals. Then cinnamon twigs are added to warm and dredge the heart meridians, and at the same time, they are used as counter-cooling drugs to assist cool drugs in dissipating blood stasis and heat in the Ying.
[0010] In the formula, Pinellia ternata is pungent and warm, dries dampness and resolves phlegm, harmonizes the stomach and stops vomiting, while Salvia miltiorrhiza breaks blood stasis in the pericardium, regulates menstruation and eliminates restlessness, calms the mind and stabilizes the spirit, and is the main drug. The assistant is Bamboo Shavings, which is sweet and slightly cold, clears heat and resolves phlegm, eliminates restlessness and stops vomiting, while Ophiopogon japonicus nourishes yin and produces body fluid, cools blood, disperses blood stasis and dredges the collaterals. The two are used together to remove qi, phlegm, turbidity, blood and collateral stasis, and regulate qi and blood, so as to restore the function of qi transformation in the triple energizer. Pinellia ternata and Bamboo Shavings are combined, one is warm and the other is cool, which can resolve phlegm and harmonize the stomach, stop vomiting and eliminate restlessness; Astragalus is an important medicine for invigorating qi, and Radix Pseudostellariae replenishes qi and nourishes yin without adding heat. The two are used together to invigorate the qi and blood of the heart; Schisandra chinensis is astringent and invigorates qi, and is used together with Astragalus and Pseudostellariae to invigorate qi, raise yang and eliminate dampness, clear qi and dampness and heat through the meridians, while nourishing yin and penetrating the collaterals, and helping the evil in the blood collaterals to return to the meridians to eliminate evil; Tangerine peel is pungent and warm, regulates qi and removes stagnation, dries dampness and resolves phlegm; Citrus aurantium is pungent and slightly cold, descends qi and guides stagnation, eliminates phlegm and eliminates lumps. Tangerine peel and Citrus aurantium are combined, one warming and one cooling, and the power of regulating qi and resolving phlegm is enhanced. With Poria cocos, it can strengthen the spleen and eliminate dampness to stop the source of phlegm; cinnamon twig warms the heart yang, dredges the blood vessels, and stops palpitations. It is used together with ginseng and wheat to promote the circulation of qi, nourish the heart, calm the mind, and restrain sweat, and transform yin with acid and sweet. It can not only prevent cinnamon twig from damaging yin due to dryness and heat, but also add yin-tonifying products to yang-tonifying, seeking yang in yin, and yang can be helped, and yin and yang are endless.
[0011] While analyzing the scientific and rationality of the drug compound of the present invention from the perspective of traditional Chinese medicine, its clinical application has also confirmed that the drug compound has a very good recovery effect on postoperative treatment of patients with myocardial infarction, can accelerate the disappearance of patients' discomfort symptoms, and promote the recovery of physical strength and energy.
[0012] Based on modern medical research, the inventors also used the drug compound to conduct animal experiments and found that the Chinese herbal compound provided by the present invention can significantly reduce the area of myocardial infarction, reduce the ventricular systolic internal diameter (LVIDs), significantly increase the left ventricular ejection fraction (LVEF) and the left ventricular shortening fraction (FS), and enhance cardiac function, indicating that the drug compound of the present invention can also have a good relief and healing effect on the treatment stage of myocardial infarction. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 .TTC staining results of mice in each group.
[0014] Figure 2 .LVIDs, LVEF and FS values of mice in each group; ** P < 0.01 vs blank; ## P < 0.01 vs model; $ P<0.05, $$ P<0.01vs Wen Dan Tang.
[0015] Figure 3 . Schematic diagram of HE pathological staining of mice in each group.
[0016] Figure 4.Statistical analysis of serological NT-proBNP ELISA test results of each group of mice. ** P < 0.01 vs blank; ## P < 0.01 vs model; $$ P<0.01vs Wen Dan Tang. DETAILED DESCRIPTION
[0017] 1. Drugs for treating myocardial infarction and repairing ischemic damage according to the present invention
[0018] Based on the clinical prescriptions for patients after myocardial infarction and in the recovery period, the inventor made the following analysis, including statistical analysis of the efficacy of prescription drugs, statistical analysis of the meridians of prescription drugs, statistical analysis of the four properties of prescription drugs, statistical analysis of the five flavors of prescription drugs, etc. Based on clinical medical records, a total of 182 related Chinese medicines were involved after statistics. Finally, combined with Ye Tianshi's Chinese medicine theory of "dampness and heat in the meridians at the beginning of the disease, blood damage in the collaterals after long-term illness", as well as clinical diagnosis and treatment experience, after a large number of experimental attempts, the following compound was explored and summarized and determined, and the compound was applied to clinical treatment, which can significantly improve the patient's cardiac function level and the accompanying discomfort symptoms, and significantly enhance energy and physical strength, proving that the compound shows a very good therapeutic effect, and the dosage of each component has a good therapeutic effect within the following weight range:
[0019] 5-10g of Pinellia ternata, 5-10g of Rhizoma Anemarrhenae, 5-10g of Immature Citrus Aurantium, 10-15g of Citrus Reticulatae, 5-15g of Poria, 10-20g of Radix Astragali, 10-20g of Radix Pseudostellariae, 10-15g of Radix Ophiopogonis, 10-15g of Radix Salviae Miltiorrhizae, 10-15g of Schisandrae Chinensis, and 5-10g of Cinnamon Twig. In traditional Chinese medicine, the dosage of corresponding drugs will be fine-tuned according to the patient's own condition. The dosage of each drug in the compound of the present invention is safe and effective when adjusted within the corresponding range.
[0020] Example: For patients after surgery and in the recovery period of myocardial infarction with phlegm and blood stasis, the following compound has better therapeutic effect: 10g of Pinellia ternata, 10g of Rhizoma Anemarrhenae, 10g of Immature Citrus Aurantium, 15g of Citrus Reticulatae, 7.5g of Poria, 15g of Astragalus, 10g of Pseudostellariae Radix, 10g of Ophiopogon japonicus, 10g of Salvia miltiorrhiza, 10g of Schisandrae Chinensis, and 5g of Cinnamon Twig.
[0021] 2. The preparation method of the drug for treating myocardial infarction and repairing ischemic damage of the present invention is as follows
[0022] The drug of the present invention is clinically called "Tongluo Wendan Decoction". The preparation process is: weigh the compound of each drug in the embodiment and mix them to obtain 112.5g, use 6 times the amount of distilled water to completely soak for 60min, decoct for 40min / time, decoct for 3 times in succession, then mix the 3 medicinal solutions and concentrate them to 50ml for use.
[0023] 3. Animal Experiments
[0024] 1. Experimental design
[0025] 1. Establishment of mouse myocardial infarction model: After inducing anesthesia in mice with isoflurane, the mice were fixed on the operating board in supine position through endotracheal intubation and ventilator. After the skin of the left anterior chest of the mice was prepared and disinfected, a wound of about 1 cm was made with surgical straight scissors, and the muscle tissue was bluntly peeled off. The heart was exposed at the 3rd to 4th intercostal space on the left side of the sternum, and the left anterior descending branch of the coronary artery was ligated with a 6-0 suture needle. The left ventricle was grayish white, and the ST segment of the two-lead electrocardiogram was elevated. The chest cavity was closed layer by layer, and the model was prepared.
[0026] 2. Experimental group: After the myocardial infarction model was successfully established, the Tongluo Wendan Decoction prepared by the above method was gavaged into the mice, and the gavage dose was 17 g / kg (raw drug amount).
[0027] 3. Control group: After the myocardial infarction model was successfully established, 62.5g of the ancient prescription Wen Dan Tang was used, including 10g of Pinellia ternata, 10g of Rhizoma Anemarrhenae, 10g of Immature Citrus aurantium, 15g of Citrus reticulata, 7.5g of Poria, 5g of ginger, and 5g of Licorice. The mice were completely soaked in 6 times the amount of distilled water for 60min, decocted for 40min each time, and decocted for 3 times in a row. Then, the 3 medicinal liquids were mixed and concentrated to 70ml for gavage. The gavage dose was 17g / kg (raw drug amount).
[0028] 4. Blank group: No surgical treatment was performed, and the same volume of normal saline was gavaged.
[0029] 5. Administration method: The administration time is 8 o'clock every morning, by gavage once a day, for 28 consecutive days.
[0030] 6. Indicator observation:
[0031] (1) 2,3,5-triphenyltetrazolium chloride (TTC) staining: After the experiment, the mice were anesthetized by intraperitoneal injection of 8% sodium pentobarbital. After perfusion, the heart tissue of the mice was quickly removed, washed with saline, and frozen for 20 to 30 minutes. The heart was sliced and placed in TTC staining solution at room temperature and away from light for 30 minutes.
[0032] (2) Cardiac function indicators (including left ventricular internal systolic diameter (LVIDs), left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (FS), etc.) are used to evaluate the contractile function of the heart through echocardiography and other techniques.
[0033] (3) Heart (HE): The fixed heart tissue was embedded in paraffin, sliced, dewaxed, gradient hydrated, nuclear stained, differentiated, gradient dehydrated, transparentized with xylene, and observed under a microscope after sealing.
[0034] (4) The mouse N-terminal pro-brain natriuretic peptide (NT-proBNP) enzyme-linked immunosorbent assay (ELISA) kit was used to detect the content of NT-proBNP in mouse heart serum.
[0035] (II) Experimental results
[0036] 1. Comparison of TTC results of mice in each group
[0037] TTC staining was performed on mice in each group, and the results showed that Figure 1 As shown, the myocardial tissue in the blank group was red, and the infarction area in the model group was grayish white. After intervention with Tongluo Wendan Decoction or Wendan Decoction, the myocardial infarction area was reduced.
[0038] 2. Comparison of cardiac function among mice in each group
[0039] M-mode ultrasound suggests Figure 2 As shown in the results, compared with the blank group, the model group had an increase in ventricular systolic internal diameter (LVIDs), and a significant decrease in left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (FS). After Tongluowendan Decoction or Wendan Decoction was given, the ventricular systolic internal diameter (LVIDs) decreased, and the left ventricular ejection fraction (LVEF) and left ventricular shortening fraction (FS) increased significantly compared with the model group. Moreover, the Tongluowendan Decoction group had a significant advantage over the Wendan Decoction group.
[0040] 3. Comparison of HE results among mice in each group
[0041] HE staining results suggest that Figure 3 As shown, compared with the blank group, the myocardial tissue in the model group was disordered, the infarcted area was white gel-like, and the texture became hard and ground glass-like. The myocardial tissue of the myocardial infarction mice that received Wen Dan Tang intervention was also disordered, and the infarcted area was also white gel-like, but the infarct area was reduced; however, in the Tongluo Wen Dan Tang group, the degree of disordered myocardial tissue arrangement was reduced, and the area of the infarcted area was significantly reduced.
[0042] 4. Comparison of NT-proBNP content in cardiac serum of mice in each group
[0043] Mouse serology was used to perform ELISA test on NT-proBNP, and the results showed that Figure 4 As shown in the data, the serum NT-proBNP level in the model group was significantly higher than that in the blank group. The NT-proBNP level in the Tongluo Wendan Decoction group was lower than that in the Wendan Decoction group after intervention treatment, and the degree of decrease after Tongluo Wendan Decoction treatment was more significant than that after Wendan Decoction treatment.
[0044] 4. Clinical Case Analysis
[0045] 1. General information: A total of 190 patients in the recovery period after myocardial infarction surgery who were admitted to outpatient clinics and hospitals were selected as research subjects, including 20 patients aged 30-40 years, 60 patients aged 40-50 years, and 110 patients aged over 50 years.
[0046] 2. Diagnostic criteria:
[0047] 2.1 Diagnostic criteria for myocardial infarction: Referring to the 2018 4th edition of the general definition of myocardial infarction, clinical evidence of myocardial ischemia includes symptoms of myocardial ischemia; new ischemic electrocardiogram changes; the appearance of pathological Q waves; new loss of viable myocardium or regional wall motion abnormalities consistent with ischemia found on imaging examinations; and coronary artery thrombosis confirmed by angiography or autopsy.
[0048] 2.2 Diagnostic criteria for TCM syndromes: refer to the State Administration of Traditional Chinese Medicine's "Diagnosis and Efficacy Criteria for TCM Diseases and Syndromes", the diagnostic criteria for chest pain and true heart pain (phlegm and blood stasis) in the "Internal Medicine" and the "Consensus on the Diagnosis and Treatment of Phlegm and Blood Stasis Syndrome with Integrated Traditional Chinese and Western Medicine".
[0049] 3. Inclusion criteria: (1) aged 35 to 85 years, regardless of gender; (2) meeting the Western medicine diagnostic criteria for myocardial infarction, successfully undergoing emergency PCI or thrombolysis, and in the recovery period of myocardial infarction (2 weeks after myocardial infarction); (3) meeting the Chinese medicine diagnostic criteria;
[0050] Exclusion criteria: (1) patients with infection or fever in the past 7 days; (2) severe arrhythmias (rapid atrial fibrillation, atrial flutter, paroxysmal ventricular tachycardia, etc.) accompanied by hemodynamic changes; (3) severe valvular heart disease (moderate lesions in one or more valves); (4) severe heart failure; (5) patients with acute exacerbation of chronic obstructive pulmonary disease, cor pulmonale, or respiratory failure; (6) patients with severe liver or kidney damage; and (7) pregnant or lactating women.
[0051] 4. Treatment method: A single-arm trial study was conducted with a standardized treatment plan for the recovery period after myocardial infarction surgery. When patients had concurrent diabetes or hypertension, hypoglycemic and antihypertensive treatment plans were given, and Tongluo Wendan Decoction was added.
[0052] Drug composition: 5-10g of Pinellia ternata, 5-10g of Rhizoma Anemarrhenae, 5-10g of Fructus Aurantii Immaturus, 10-15g of Pericarpium Citri Reticulatae, 10-15g of Poria, 10-20g of Radix Astragali, 10-20g of Radix Pseudostellariae, 10-15g of Radix Ophiopogonis, 10-15g of Radix Salviae Miltiorrhizae, 10-15g of Fructus Schisandrae Chinensis, 5-10g of Cinnamon Twig. Decoction, warm and take 30 minutes after meals in the morning and evening. Follow-up visit once every 1-2 weeks, medication cycle for 2 months, combined with the four diagnostic conditions of the patient, syndrome differentiation and treatment, reasonable adjustment of the specific dosage of the drug within the above dosage range.
[0053] 5. Clinical efficacy evaluation criteria:
[0054] Marked effect: ECG shows that pathological changes are significantly improved, discomfort symptoms disappear, and energy and physical strength are significantly enhanced;
[0055] Improvement: ECG shows that pathological changes have improved, discomfort symptoms have been alleviated or partially disappeared, and energy and physical strength have increased;
[0056] Ineffective: Symptoms and signs are not improved or are aggravated.
[0057] The TCM syndrome score was formulated with reference to the State Administration of Traditional Chinese Medicine's "Standards for Diagnosis and Efficacy of TCM Diseases and Syndromes", "Chinese Internal Medicine", and "Guidelines for Clinical Research of New Chinese Medicines". Based on the severity of the patient's symptoms, the corresponding main symptoms and concomitant symptoms were recorded as 0, 1, 2, 3, 4, and 6 points, respectively. The changes in the TCM symptom scores before and after the treatment with Tongluo Wendan Decoction were recorded.
[0058] 5.1 Treatment Outcomes
[0059]
[0060] 5.2 Comparison of TCM syndrome scores before and after treatment
[0061]
[0062] Δ is the difference between the syndrome score at the first visit and the TCM syndrome score at the end of the visit; compared with the group before and after treatment, # P<0.05.
[0063] 5.3 Comparison of cardiac structure and function
[0064]
[0065] Echocardiography was used to measure the left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), and left ventricular end-systolic diameter (LVESD). Compared with those before treatment, # P<0.05.
[0066] 5.4 Comparison of serum NT-proBNP levels
[0067]
[0068] The fasting serum NT-proBNP levels of the patients were measured in the morning before and after treatment, and compared with those before treatment. # P<0.05.
[0069] In the treatment with Tongluo Wendan Decoction, 190 patients were treated with the drug of the present invention, 120 of them were significantly effective, 70 were improved, and no one was ineffective, with a total effective rate of 100%. The drug is easy to use, and the patients have good compliance during the medication process, and the patient recognition and drug safety are high. In addition, clinical application studies have confirmed that the drug of the present invention can well improve the TCM syndrome score and cardiac function level of patients after myocardial infarction surgery and in the recovery period, showing a good therapeutic effect.
Claims
1. A drug for postoperative recovery treatment of myocardial infarction, Features Including raw materials within the following weight range: Pinellia ternata 5-10g, Rhizoma Anemarrhenae 5-10g, Immature Citrus aurantium 5-10g, Citrus reticulatae 10-15g, Poria 5-15g, Astragalus 10-20g, Pseudostellariae Radix 10-20g, Ophiopogon japonicus 10-15g, Salvia miltiorrhiza 10-15g, Schisandra chinensis 10-15g, and Cinnamon twig 5-10g.
2. A drug for postoperative recovery treatment of myocardial infarction according to claim 1, Features: The dosage of each raw material is: 10g of Pinellia ternata, 10g of Rhizoma Anemarrhenae, 10g of Immature Citrus aurantium, 15g of Citrus reticulata, 7.5g of Poria, 15g of Astragalus, 10g of Pseudostellariae Radix, 10g of Ophiopogon japonicus, 10g of Salvia miltiorrhiza, 10g of Schisandrae Chinensis, and 5g of Cinnamon Twig.
Citation Information
Patent Citations
Prescription for treating myocardial infarction and preparation method of prescription
CN106822775A
Traditional Chinese medicine composition for secondary prevention of qi deficiency and blood stasis syndrome myocardial infarction
CN108186877A
Chinese medicinal composition for regulating and supplementing pectoral qi
CN111000937A
Traditional Chinese medicine composition for treating acute myocardial infarction and traditional Chinese medicine preparation and application thereof
CN114848775A
Traditional Chinese medicine composition for treating myocardial infarction as well as preparation method and application thereof
CN116726124A
